首页> 中文期刊>中国老年保健医学 >肿瘤化疗致Ⅳ度骨髓抑制临床观察与分析

肿瘤化疗致Ⅳ度骨髓抑制临床观察与分析

     

摘要

Objectives The aim of this study is to explore the treatment and prevention measures ofⅣdegrees myelosuppression caused by conventional-dose chemotherapy.Methods 2756 cases of malignant tumor patients in our hospital were enrolled.We in-vestigated the age, sex, therapy and other information of patients who occurred Ⅳ degrees myelosuppressionbone, summarized its regularity and problems, and proposed solutions or recommendations.Results There were 35 cases with Ⅳ degrees myelosuppres-sion, of which taxane has the highest incidence, followed by pemetrexed, irinotecan, S-1, CHOP regimen.The degree of myelosup-pression was positively correlated with the infection rate, but no correlation with gender and age.Conclusions Ⅳ degreesmyelo-suppression has great impact on the cancerous patients with chemotherapy, which often lead to chemotherapy disruption or failure, and even death.Therefore, it is necessary to use preventive drug in time, pay attention to improve immunity, strengthen nursing and prevent infection and death.%目的:探讨常规剂量化疗后Ⅳ度骨髓抑制的处理及防治措施。方法选取我院恶性肿瘤患者2756例次,调查发生Ⅳ骨髓抑制患者的年龄、性别、治疗方案等信息,探索其规律性及存在的问题,提出解决的办法或建议。结果收集共发生Ⅳ骨髓抑制35例次,其中以紫杉类骨髓抑制发生率最高,其次是培美曲塞、伊立替康、替吉奥、CHOP方案等;骨髓抑制程度与感染率呈正向关系,与性别、年龄无显著差异。结论Ⅳ骨髓抑制对肿瘤患者的化疗影响较大,常常导致化疗的中断或失败,严重导致患者死亡。因此,要及时使用预防药物、注意提高机体免疫力、加强护理、防止感染和死亡。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号